Schülin T, Wennersten C B, Moellering R C, Eliopoulos G M
Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02115, USA.
J Antimicrob Chemother. 1998 Sep;42(3):297-301. doi: 10.1093/jac/42.3.297.
The comparative in-vitro activity of HMR 3647, a new ketolide antibiotic, was investigated against 492 clinical isolates of gram-positive bacteria, including multiply resistant strains, by an agar-dilution technique. All streptococci tested were inhibited by the new ketolide at concentrations < or = 0.5 mg/L. HMR 3647 was more potent than erythromycin against staphylococci. For enterococci the new compound yielded an MIC90 of 8 mg/L. Erysipelothrix spp., Pediococcus spp., Leuconostoc spp., Lactobacillus spp., JK diphtheroids and Listeria monocytogenes were also susceptible to the new ketolide.
采用琼脂稀释法，对一种新型酮内酯类抗生素HMR 3647针对492株革兰氏阳性菌临床分离株（包括多重耐药菌株）的体外活性进行了比较研究。所有受试链球菌均被该新型酮内酯类抗生素在浓度≤0.5mg/L时所抑制。HMR 3647对葡萄球菌的活性比红霉素更强。对于肠球菌，该新型化合物的MIC90为8mg/L。丹毒丝菌属、片球菌属、明串珠菌属、乳杆菌属、JK类白喉杆菌和单核细胞增生李斯特菌也对该新型酮内酯类抗生素敏感。
